Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 176

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 176
---
The following table summarizes our cash flows for the periods presented:

    Year EndedDecember 31,

    2024

    2023

    Net cash used in operating activities
     
    $
    (18,321,276
    )
     
    $
    (7,286,286
    )

    Net cash used in investing activities

    (19,171
    )

    -

    Net cash provided by financing activities

    12,847,764

    14,025,008

    Net (decrease) increase in cash and cash equivalents
     
    $
    (5,492,683
    )
     
    $
    6,738,722

Net Cash Used in Operating Activities

During the year ended December 31, 2024, net cash used in operating activities was $18.3 million, which consisted of a net loss of $15.0 million and a net change of $3.4 million in our net operating assets and liabilities.

During the year ended December 31, 2023, net cash used in operating activities was $7.3 million, which consisted of a net income of $0.1 million and a net change of $8.1 million comprised of the change in fair value of the warrant liability, stock-based compensation expense and depreciation expense, offset by a net change of $1.0 million in our net operating assets and liabilities.

Net Cash Used in Investing Activities

During the year ended December 31, 2024, net cash used in investing activities consisted of a purchase of lab equipment.

During the year ended December 31, 2023, there was no cash used in investing activities. 

Net Cash Provided by Financing Activities

During the year ended December 31, 2024, net cash provided by financing activities was $12.8 million, from net proceeds of $5.4 million received in connection with the February 2024 Public Offering (defined below), $0.2 million received from exercises of the Class D Common Stock Warrants (defined below), net proceeds of $3.5 million received in connection with the Class D Warrant Inducement (defined below) and net proceeds of $3.7 million received in connection with the Class E Warrant Inducement (defined below).

During the year ended December 31, 2023, net cash provided by financing activities was $14.0 million from the February 2023 Public Offering (defined below).

 66